Key result
Post-radiation JNJ-26366821 curbs cardiac inflammation and promotes tissue maintenance pathways in preclinical models.
Why the study?
Cardiomyopathy is a leading cause of mortality due to delayed radiotoxic effects, and thrombopoietin mimetics were evaluated for mitigating these impacts following radiation exposure.
Does JNJ-26366821 reduce systemic inflammation and mitigate cardiotoxic risk in a mouse model of lethal radiation exposure?
Does JNJ-26366821 reduce systemic inflammation and mitigate cardiotoxic risk in a mouse model of lethal radiation exposure?
JNJ-26366821, a novel thrombopoietin mimetic, attenuates systemic inflammation and activates pathways supporting cellular homeostasis in the heart following lethal radiation exposure in mice.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for JNJ-26366821 as radiation countermeasure; leaves open human translation and clinical testing.
Introduction: Thrombopoietin mimetics (TPOm) are known to increase blood cell counts, thereby ameliorating various diseases, including cardiomyopathy—a leading cause of mortality because of delayed radiotoxic effects. Previous preclinical studies demonstrated significant survival enhancement following lethal radiation exposure with a single dose of JNJ-26366821 in two mouse strains, CD2F1 and C57BL/6. Materials and Methods: In this study, a single dose of JNJ-26366821 (1.0 mg/kg) or saline was administered 24 h post-8.0 Gy total body irradiation (TBI) to male C57BL/6 mice. Mice were euthanized on days 1, 7, 15, and 30 post-TBI, and serum and heart samples were collected. Unirradiated mice treated with saline served as baseline controls. Inflammatory serum cytokines/chemokines, growth factors and multi-omics analyses, including proteomics, metabolomics, and lipidomics, were evaluated to assess therapeutic impacts. Results: JNJ-26366821 demonstrated overall positive effects, restraining radiation-induced inflammatory surges by 7 days post-TBI. Functional analysis revealed that JNJ-26366821 treatment in unirradiated mice activated cellular homeostasis, which persisted after post-exposure intervention in irradiated mice. The drug immediately reduced cell death, but networks supporting cardiovascular health, such as angiogenesis and vasculogenesis, remained inhibited 2 h post-intervention. By 7 days post-TBI, JNJ-26366821 mobilized molecules in heart tissue to reconstitute cellular development and maintenance. Protein synthesis and metabolism were activated between 15 and 30 days post-TBI, potentially compensating for radiation-induced muscle wasting. Conclusions: JNJ-26366821 demonstrated promising mitigating effects on cellular homeostasis and cardiovascular health when administered as a single dose at 24 h post-exposure.
No takes yet. Share an insight, caveat, or question.
Chakraborty et al. (2026) studied Acute radiation syndrome and radiation-induced heart damage. JNJ-26366821 vs. Saline was evaluated on Inflammatory serum cytokines and heart multi-omics profiles. A single dose of JNJ-26366821 administered 24 hours post-irradiation restrained inflammatory surges and mobilized molecules in heart tissue to reconstitute cellular development and maintenance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: